Treating metastatic melanoma with Stereotactic Ablative Body Radiotherapy and IMmune Pathway ACTivation (SABR-IMPACT)

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1090906

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Metastatic melanoma has historically had extremely poor survival. Drugs that activate the immune system provide some hope, and in the minority who respond survival beyond 10 years is possible. Radiotherapy causes local tumour death resulting in antigen exposure and systemic effects that may also stimulate the immune system. The combination of radiotherapy and immune activating drugs may be synergistic and result in improved survival for a greater proportion of patients.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2018

Funding Scheme: Early Career Fellowships

Funding Amount: $185,445.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Solid Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

immune modulation | immunotherapy | melanoma | metastatic cancer | radiation therapy

Related Links